Aptevo Therapeutics (APVO)
(Delayed Data from NSDQ)
$0.35 USD
-0.02 (-5.00%)
Updated Aug 28, 2024 03:58 PM ET
After-Market: $0.34 -0.01 (-3.30%) 7:44 PM ET
2-Buy of 5 2
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Aptevo Therapeutics Inc. [APVO]
Reports for Purchase
Showing records 21 - 40 ( 98 total )
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in ALG.APV-527 Phase 1 Trial in 5T4+ Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Outperforms In Venetoclax Naive AML, Phase 2 Should Start In 2H23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q22: APVO436 Progressing, New Clinical Trials to Start, Cash to Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Publication Demonstrates Promise of ALG.APV-527
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q22: APVO436 Progressing, New Clinical Trials to Start, Cash to Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Four New Remissions Seen in Phase 1b APVO436 Dose Expansion Trial for AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
A 2nd Phase 1b AML Patient Rendered Eligible for Allogeneic Transplant
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q21: APVO436 Showing Early Phase 1b Promise, Cash Through at Least 1Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Reasons to Sit Down with These Biotech Managements at the 2022 Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Aptevo Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
APVO436 Trial Attracts MD Anderson, Ruxience Thus Far Selling as Expected
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J